New Single-Use Fermentor Brings Microbial Applications Up to Speed
A new single-use fermentor matches the performance of stainless steel while eliminating clean/steam-in-place steps, reducing set-up time and mitigating cross-contamination risk in microbial fermentation.
The Thermo Scientific HyPerforma Single-Use Fermentor (SUF) is the first single-use system specifically engineered for microbial fermentation and designed to scale up from the lab to GMP production. Capable of meeting the aggressive performance demands of industrial microbiology, the HyPerforma SUF integrates into existing Thermo Scientific single-use technologies to achieve exceptional efficiency and scalability across the entire bioprocessing workflow.
Thermo Fisher will showcase its new HyPerforma Single-Use Fermentor this week at the BioProcess International Conference and Exhibition, 21–23 October 2014 at the Hynes Convention Center, Booth #301.
“Until now, fermentation equipment has been hard to convert to single-use due to the aggressive demands of fast-growing microbial cultures. Modified single-use bioreactors have been used, but are not designed for ideal growth conditions,” said Daniel Nelson, product manager, single-use systems at Thermo Fisher Scientific. “Through engineering an innovative, single-use exhaust and condenser system, coupled with powerful mixing, we overcame constraints in oxygen transfer to create the first purpose-built single-use fermentor. The HyPerforma SUF is a natural progression developed specifically for fermentation processes and a dedicated tool needed to increase choice, flexibility and performance for all bioprocessing workflows.”
Key product features include:
• Effective mass transfer, powerful mixing, and temperature control using three Rushton-style impellers and baffled, jacketed vessel
• 5:1 turndown ratio and 3:1 height-to-diameter ratio for consistent scalability and flexibility of process design (both 30 L and 300 L models).
• Efficient exhaust management system, enabling high flow rates (2VVM)
• Vertical access door for easy loading and retrieval of the bioprocess containers and harvest lines.
• Turn-around times between batches as low as 2 hours.
As a two-part product, the HyPerforma SUF comes paired with a Thermo Scientific BioProcess Container (BPC) — pre-sterilised and gamma irradiated. With an open architecture design, the HyPerforma SUF with BPC is highly flexible. It can also be retrofitted into existing fermentor operations, as well as configured to operate with existing software and control equipment, or delivered turnkey for immediate use.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance